Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-linker conjugate for ADC
APL-1091 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises the Mal-Exo-EEVC linker, which facilitates the attachment to antibodies, and MMAE, a potent microtubule inhibitor that disrupts cellular mitosis. This compound is essential for the synthesis of ADCs, enabling targeted delivery of cytotoxic agents to cancer cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugates for ADC
Val-Cit-PAB-DEA-Dxd is a versatile drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound integrates a cleavable linker with the potent DNA topoisomerase I inhibitor Dxd, facilitating targeted delivery of the cytotoxic agent. Val-Cit-PAB-DEA-Dxd is suitable for synthesis of ADCs aimed at enhancing therapeutic efficacy in cancer research. -
Drug-Linker Conjugate for ADC
Tub114 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound is an analog of Tubulysin B, featuring a stable hydrophilic linker that enhances its suitability for the synthesis of ADCs. Tub114 exhibits key biological activity by selectively targeting and inhibiting tumor cell proliferation, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugates for ADC
PC6-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound combines the cytotoxic agent MMAE with a specialized linker, facilitating targeted delivery and enhanced therapeutic efficacy. PC6-VC-PAB-MMAE is suitable for the synthesis of ADCs, enabling focused research in cancer treatment and the development of innovative therapeutic strategies. -
Drug-Linker Conjugate for ADC
MC7 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This reagent features a payload that acts as a NAMPT inhibitor, facilitating targeted therapeutic delivery in cancer research. It is an essential tool for developing ADCs aimed at enhancing the efficacy of chemotherapy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-betaglucuronide-MMAE-2 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs), leveraging the potent antitumor activity of MMAE, a known tubulin polymerization inhibitor. The conjugate features a cleavable linker, MC-betaglucuronide, facilitating targeted delivery and release of the cytotoxic agent within tumor cells. This compound is suitable for research applications in oncology and cancer therapeutics, specifically in studies focused on ADC efficacy and mechanism of action. -
Drug-Linker Conjugates for ADC
Mal-PEG8-Val-Ala-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features the potent cytotoxic agent Exatecan linked through a flexible PEG8 spacer, enhancing its therapeutic efficacy. It is primarily utilized in the synthesis of ADCs to selectively deliver drugs to target cells, thereby improving the specificity and reducing off-target effects in cancer therapy research. -
Drug-Linker Conjugates for ADC
Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features a mal-amido group linked to a PEG8 spacer and is optimized for efficient drug delivery and targeting. It enables the precise attachment of cytotoxic agents to antibodies, enhancing targeted therapeutic efficacy in cancer research and treatment development. -
Drug-Linker Conjugates for ADC
LE01 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It incorporates a linker suitable for ADC synthesis and the DNA topoisomerase I inhibitor DXd, facilitating targeted therapy. LE01 is particularly useful in generating HER2-targeting ADCs, enabling selective delivery of cytotoxic agents to HER2-expressing tumors for enhanced therapeutic efficacy. -
ADC Linker
diSPhMC-Asn-Pro-Val-PABC-MMAE is an effective ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of therapeutic agents to target cells, enhancing the efficacy of cancer treatment while minimizing systemic toxicity. It is suitable for applications in targeted therapy research and the development of novel ADC formulations. -
Drug-Linker Conjugates for ADC
Mal-VC-PAB-PNP-CDN-A is a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. It employs a maleimide-based thiol-reactive mechanism to facilitate the site-specific attachment of cytotoxic drugs to monoclonal antibodies. This compound enhances the efficacy of ADCs by improving stability and targeted delivery, making it a valuable tool in cancer research and therapeutic development. -
Drug-linker conjugate for ADC
Fmoc-Gly-Gly-Phe-Gly-Docetaxel is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features a microtubule depolymerization inhibitor, Docetaxel, linked through a peptide moiety, enabling targeted delivery of the cytotoxic agent to cancer cells. It is suitable for research applications focused on the development of ADC therapeutics for enhanced anti-cancer efficacy. -
Drug-Linker Conjugate for ADC
Mal-Toxophore is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. It features a payload that acts as a NAMPT inhibitor, contributing to targeted therapeutic efficacy. This compound is instrumental for researchers investigating ADC applications in cancer therapy and related fields, enabling the selective delivery of cytotoxic agents to cancer cells. -
Drug-Linker Conjugates for ADC
ST8154AA1 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that targets histone deacetylases (HDACs). This compound exhibits potent antitumor activity, making it a valuable tool for cancer research. Its application is particularly relevant in studies focused on developing targeted therapies and enhancing the efficacy of ADCs in oncology. -
ADC Linker
Asn-Pro-Val-PABC-MMAE TFA is an effective ADC linker designed for the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic drugs to antibodies, enhancing targeted delivery and therapeutic efficacy. It is a valuable tool for researchers focused on developing novel ADC therapies for cancer treatment and other diseases. -
Drug-Linker Conjugate For ADC
BrAc-Galactose-Sar-N-Me-alanine-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the conjugation with anti-TM4SF1 antibodies, enhancing targeted delivery of cytotoxic agents in cancer therapeutics. Its precise structural attributes enable efficient synthesis and potential for significant biological activity in research focused on ADC development and tumor targeting. -
Drug-Linker Conjugates for ADC
MMAE-PAB(p-glucuronide)-PEG3-aminooxy is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents, enhancing therapeutic efficacy while minimizing off-target effects. Its unique structure allows for stable attachment to antibodies, making it suitable for research applications in cancer therapy and drug development. -
Drug-Linker Conjugates for ADC
CL2E-SN38 is a potent drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features SN-38, the active metabolite of Irinotecan, which acts as a Topoisomerase I inhibitor, disrupting DNA replication and transcription. Given its high release potential and structural stability, CL2E-SN38 is suitable for advanced cancer therapeutics research and the development of targeted treatments with reduced systemic toxicity. -
Drug-Linker Conjugates for ADC
G3-VC-PAB-DMEA-Duocarmycin DM is a duocarmycin-based drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs). This linker selectively releases the duocarmycin moiety upon internalization, leading to targeted cytotoxicity against cancer cells. Its applications include enhancing therapeutic efficacy in oncology research by selectively delivering cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates targeted delivery of cytotoxic agents to specific cells through selective binding to antibody moieties. It is useful in research focused on cancer therapeutics, enabling the study of immunoconjugate efficacy and safety profiles in various preclinical models. -
Drug-Linker Conjugate for ADC
Modified MMAF-C5-COOH is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It exhibits potent cytotoxic activity through the release of MMAF (monomethyl auristatin F), targeting and eliminating cancerous cells while minimizing damage to healthy tissues. This compound is essential for researchers developing ADC strategies for targeted cancer therapies. -
Drug-Linker Conjugates for ADC
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan is a linker utilized for the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic agents to target antibodies, enhancing selective delivery to tumor cells. ADCs synthesized with Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan demonstrate significant antitumor efficacy both in vitro and in vivo, making it a valuable reagent for cancer research and therapeutic applications. -
Drug-Linker Conjugates for ADC
Fmoc-Gly-Gly-Phe-Gly-Paclitaxel is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound combines the Fmoc-Gly-Gly-Phe-OH linker with the potent tubulin polymerization inhibitor, Paclitaxel, facilitating targeted delivery in cancer research. Its unique structure enables the selective treatment of tumor cells, making it a valuable tool for studying ADC efficacy and mechanisms in oncology. -
Drug-linker Conjugate for ADC
DMBA-SIL-Mal-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent antitumor cytotoxin monomethyl auristatin E (MMAE), a tubulin inhibitor. This compound provides targeted delivery of MMAE to cancer cells via a stable linkage with DMBA-SIL-Mal, enhancing its therapeutic efficacy. It serves as a valuable tool for researchers investigating ADCs in cancer therapy and drug development. -
Drug-Linker Conjugates for ADC
ADC-VI is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), utilizing Deruxtecan as the cytotoxic agent. This compound facilitates targeted delivery by chemically linking Tricyclene to an anti-FGFR2b antibody through a conjugation reaction. ADC-VI is primarily employed in research applications focused on enhancing the efficacy and selectivity of cancer therapeutics, particularly in tumors expressing FGFR2b. -
Drug-Linker Conjugate for ADC
STING agonist-49-CO-C2-mal is a non-cleavable drug-linker conjugate designed for antibody-drug conjugates (ADCs) targeting the STING pathway. This compound serves as a crucial component in the synthesis of ADCs, enabling targeted delivery of cytotoxic agents to enhance therapeutic efficacy in cancer research. With its dual functionality—acting as both a target protein ligand and an E3 ligase ligand—STING agonist-49-CO-C2-mal facilitates the development of innovative cancer therapies through precise modulation of immune responses. -
Drug-Linker Conjugates for ADC
Tismanitin maleimide functions as a linker-cargo component in antibody-drug conjugates (ADCs). It enables the covalent attachment of monoclonal antibodies (mAbs) through a cleavable linker, thereby facilitating targeted anti-cancer therapies. This reagent is particularly valuable for research applications focused on multiple myeloma. -
Drug-Linker Conjugate for ADC
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a quinoline-based payload that acts as a nicotinamide adenine dinucleotide (NAD+) biosynthesis inhibitor, specifically targeting NAMPT. It is suitable for research focused on developing ADCs for targeted cancer therapies, enhancing selective cytotoxicity while minimizing effects on healthy tissues. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents to specific cells, enhancing therapeutic efficacy while minimizing off-target effects. It is ideal for research applications in cancer therapy and drug development, particularly in optimizing ADC formulations. -
Drug-Linker Conjugate for ADC
STING agonist-49-PAB-Ala-Val-CO-C2-mal is a drug-linker conjugate designed for antibody-drug conjugate (ADC) synthesis. This compound functions as a pep-cSTING linker-payload, promoting the activation of the STING pathway to enhance therapeutic efficacy. Its applications include facilitating targeted delivery of cytotoxic agents to enhance anti-tumor immunity and investigating the role of STING in immune modulation. This versatile agent is instrumental for research in targeted therapeutics and immune-related studies. -
Drug-linker Conjugate for ADC
MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing efficacy while minimizing systemic toxicity. Its applications extend to cancer research and the investigation of autoimmune diseases, contributing to the development of innovative therapeutic strategies. -
Drug-Linker Conjugate for ADC
Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This molecule features the potent antitumor agent Calicheamicin, linked via a novel chemical moiety to facilitate selective delivery to tumor cells. It serves as a critical component in the synthesis of ADCs, such as PF-06647263, and is essential for advancing research in targeted cancer therapies. -
Drug-Linker Conjugate for ADC
Glucocorticoid receptor modulator 4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound demonstrates glucocorticoid receptor (GRE) reporter activation in mTNF-expressing K562 cells with an EC50 of 40 μM. Additionally, it exhibits binding affinity with anti-tumor necrosis factor (TNF) antibodies and exhibits anti-inflammatory effects in mouse models of arthritis, making it a valuable tool for research in inflammation and autoimmune diseases. -
Drug-Linker Conjugate for ADC
MC-GGFG-3-Methylenecyclobutyl-Exatecan functions as a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the potent cytotoxic properties of Exatecan with a specialized linker, facilitating targeted delivery of therapeutics to cancer cells. It is invaluable for researchers involved in ADC synthesis and development, contributing to advancements in targeted cancer therapies. -
Drug-linker Conjugate for ADC
P5(PEG12)-VC-PAB-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), targeting the DNA topoisomerase I enzyme. This compound combines the potent antitumor activity of Exatecan with the cleavable linker P5(PEG12)-VC-PAB, providing a targeted approach to cancer therapy. It serves as a valuable tool for research applications focused on tumor treatment and the mechanism of ADC efficacy. -
Drug-Linker Conjugate for ADC
LD-38 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a topoisomerase I inhibitor, Exatecan, with a stable, cleavable linker that enhances hydrophilicity. This compound is ideal for the synthesis of various ADCs, including KA-3123-LD38, and is utilized in research focusing on targeted cancer therapies and drug delivery systems. -
Antibody-drug Conjugates
(R)-DM4-SPDP is a conjugate consisting of the linker SPDP and the cytotoxic agent DM4, specifically designed for the development of antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of therapeutic agents to tumor cells, enhancing the efficacy of cancer treatment while minimizing systemic toxicity. (R)-DM4-SPDP is ideal for research applications focused on ADC design and optimization in oncology studies. -
Antibody-drug Conjugate (ADC)
Rolinsatamab talirine is an antibody-drug conjugate (ADC) designed to target the prolactin receptor (PRLR). This compound combines rolinsatamab with an enzymatically cleavable peptide linker and SGD-1882, facilitating targeted drug delivery to cells expressing the PRLR. Rolinsatamab talirine exhibits potent biological activity, making it suitable for research applications in cancer therapeutics and receptor-targeted drug development. -
Drug-Linker Conjugates for ADC
Mal-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) formulations. This compound consists of a maleimide linker combined with the cytotoxic agent PNU-159682, exhibiting significant anti-tumor activity. Its applications include enhancing the targeted delivery of therapeutics in cancer research and improving the efficacy of cancer treatment through ADC technology. -
Drug-Linker Conjugates for ADC
Val-Ala-PABC-N(Mesylpropane)-Exatecan is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Exatecan, a potent inhibitor of DNA topoisomerase I, linked via a cleavable Val-Ala-PABC-N(Mesylpropane) moiety. It is intended for research applications focused on targeted cancer therapies, enhancing the selectivity and efficacy of antitumor agents. -
Drug-Linker Conjugates for ADC
DM1-MCC-PEG3-Biotin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound effectively links the potent cytotoxic agent DM1 with biotin via a stable MCC (maleimidocaproic acid) and PEG3 spacer, facilitating targeted delivery of therapeutics by conjugating to biotin-binding antibodies. It is particularly valuable in research focused on developing and optimizing ADCs for cancer treatment, enabling enhanced therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugates for ADC
Mal-Val-Ala-amide-(3)PEA-PNU-159682 is a drug-linker conjugate designed for targeted antibody-drug conjugate (ADC) applications. This compound features an ADC linker, Mal-Val-Ala-amide-(3)PEA, which is covalently bonded to the cytotoxic agent PNU-159682, exhibiting notable anti-tumor activity. It is suitable for research into cancer therapies, utilizing precise delivery mechanisms to enhance therapeutic efficacy while minimizing off-target effects. -
Antibody-Drug Conjugates
Ifinatamab deruxtecan is an antibody-drug conjugate that targets B7-H3, linking an anti-B7-H3 antibody to the DNA topoisomerase I inhibitor DXd. This compound exhibits significant antitumor activity, making it a valuable tool for research in oncology. It is particularly relevant for studies focused on targeted delivery of therapeutic agents in cancer treatment. -
Antibody-Drug Conjugate
Tisotumab vedotin is an antibody-drug conjugate (ADC) that targets tissue factor (TF). This compound is designed by covalently linking a fully human monoclonal antibody (TF-011) to the microtubule disruptor Monomethyll Auristatin E (MMAE) through the VcMMAE linker. Tisotumab vedotin exhibits immunomodulatory and anti-tumor activities, making it a valuable tool for researching advanced or metastatic solid tumors, including cervical cancer. -
Antibody-Drug Conjugate
Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FRA) using the humanized anti-FRA antibody Farletuzumab. Conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin, this compound features an agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin exhibits significant cytotoxicity towards FRA-positive cancer cells and demonstrates potent antitumor activity, making it a valuable reagent for research in targeted cancer therapies. -
ADC Cytotoxin
Exatecan Intermediate 2 is an important precursor in the synthesis of Exatecan, a camptothecin analog with potent anticancer properties. This compound targets DNA, disrupting the proliferation and division of tumor cells, thereby inhibiting tumor growth. It is primarily employed in research focused on various cancers, including ovarian, lung, and breast cancers, making it a valuable tool in oncology studies. -
ADC Cytotoxin
Cyclopropaneacetamide-Exatecan is an analogue of Exatecan, functioning as an ADC (antibody-drug conjugate) cytotoxin. Its primary mechanism involves targeting cancer cells to deliver cytotoxic agents selectively, enabling effective tumor treatment. This compound is instrumental in the synthesis of ADC molecules and is valuable for research applications focused on cancer therapeutics and drug delivery systems. -
ADC Cytotoxin
7-MAD-MDCPT is a potent Camptothecin analog designed as a cytotoxic agent in antibody-drug conjugates (ADCs). Its primary mechanism involves the inhibition of topoisomerase I, leading to DNA damage and subsequent apoptosis in proliferating cells. This compound is utilized in the development of targeted cancer therapies, enhancing the effectiveness and specificity of ADCs in oncology research. -
ADC Cytotoxin
PBD-monoamide, a modified pyrrolobenzodiazepine (PBD) dimer, serves as an antibody-drug conjugate (ADC) cytotoxin. This compound exhibits DNA-binding activity, leading to reduced cell viability, making it a valuable tool for cancer research. PBD-monoamide is utilized in the synthesis of DHES0815A, an ADC targeting HER2, facilitating the study of targeted cancer therapies. -
ADC Cytotoxin/TopI Inhibitor
ZD06519 is a potent ADC cytotoxin and a topoisomerase I inhibitor derived from camptothecin. It exhibits a significant bystander effect, effectively inhibiting various malignancies, including HER2-positive and FRα-overexpressing tumors. By interfering with DNA cleavage, relaxation, and reconnection, ZD06519 induces apoptosis in tumor cells. This compound is ideal for ADC synthesis and applications in cancer research.
